Vivo Capital’s Pharvaris PHVS Stock Holding History

Vivo Capital’s Portfolio PHVS Stock Details PHVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-285,000	Closed	-$7.99M	–	47
2023 Q4	$7.99M	Buy	+285,000	New	+$5.77M	0.65%	30

Other funds holding PHVS

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Viking Global Investors

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Vivo Capital's PHVS Position: Q1 2024 in Review

Vivo Capital sold out of Pharvaris (PHVS) in Q1 2024, closing a stake of 285,000 shares — an estimated $7.99M sold.

Vivo Capital first reported a position in PHVS in Q4 2023 and held it in 1 quarter. The position peaked at $7.99M in Q4 2023. 35 funds tracked by Wall St. Rank hold PHVS as of Q1 2024.

Vivo Capital reported no remaining Pharvaris position as of Q1 2024 after selling out during the quarter.
Vivo Capital sold 285,000 Pharvaris shares in Q1 2024, an estimated $7.99M.
Vivo Capital first reported a position in Pharvaris in Q4 2023 and held it in 1 quarter.
Vivo Capital's Pharvaris position peaked at $7.99M in Q4 2023.
35 funds tracked by Wall St. Rank held Pharvaris as of Q1 2024.

Based on Vivo Capital's 13F filing for Q1 2024, filed 22 Apr 2024.